Sam Brusco, Associate Editor11.28.23
Apyx Medical Corporation, maker of Renuvion helium plasma and radiofrequency (RF) technology, has appointed Matthew Hill as its new chief financial officer (CFO), effective December 4. Hill succeeds Tara Semb, whose departure was announced by Apyx on November 9.
“Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the chief financial officer of four publicly-traded healthcare companies,” Apyx president and CEO said Charlie Goodwin told the press. “I’m pleased to welcome Matt to Apyx Medical and look forward to working with him to execute our strategic initiatives and position the Company to deliver strong, sustainable, long-term growth.”
Hill was most recently CFO of clinical-stage immunotherapy company PDS Biotech. Before PDS Biotech, he was CFO of Strata Skin Sciences, a company that makes products to treat dermatologic conditions, from 2018 to 2021.
Before Strata, Hill held the chief finance role at several companies, including Velcera (pet medication for the companion animal health industry) and EP MedSystems (cardiac electrophysiology products). He was also a senior manage at international accounting and consulting firm Grant Thornton LLP.
“With its innovative Renuvion technology, large, global market opportunity, recent operational progress and an enhanced balance sheet, I believe Apyx Medical is well-positioned for future success in the cosmetic surgery market,” said Hill. “I am pleased to join the company at this exciting time, and look forward to working with Charlie and the rest of the team as we lead Apyx Medical through its next stage of growth and development.”
Apyx’s Renuvion Micro handpiece was granted U.S. Food and Drug Administration (FDA) 510(k) clearance in June.
“Matt joins our executive leadership team with over 30 years of financial and operational experience, more than 20 years of which has been in the healthcare industry, where he has served as the chief financial officer of four publicly-traded healthcare companies,” Apyx president and CEO said Charlie Goodwin told the press. “I’m pleased to welcome Matt to Apyx Medical and look forward to working with him to execute our strategic initiatives and position the Company to deliver strong, sustainable, long-term growth.”
Hill was most recently CFO of clinical-stage immunotherapy company PDS Biotech. Before PDS Biotech, he was CFO of Strata Skin Sciences, a company that makes products to treat dermatologic conditions, from 2018 to 2021.
Before Strata, Hill held the chief finance role at several companies, including Velcera (pet medication for the companion animal health industry) and EP MedSystems (cardiac electrophysiology products). He was also a senior manage at international accounting and consulting firm Grant Thornton LLP.
“With its innovative Renuvion technology, large, global market opportunity, recent operational progress and an enhanced balance sheet, I believe Apyx Medical is well-positioned for future success in the cosmetic surgery market,” said Hill. “I am pleased to join the company at this exciting time, and look forward to working with Charlie and the rest of the team as we lead Apyx Medical through its next stage of growth and development.”
Apyx’s Renuvion Micro handpiece was granted U.S. Food and Drug Administration (FDA) 510(k) clearance in June.